- Home
- PESI vs CRVS Comparison
PESI vs CRVS Comparison
Compare PESI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PESI | CRVS |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 1.7B |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PESI | CRVS |
|---|---|---|
| Price | $10.86 | $14.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.20 |
| AVG Volume (30 Days) | 170.4K | ★ 1.1M |
| Earning Date | 03-24-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.61 | ★ 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,000.00 | N/A |
| Revenue This Year | $71.17 | N/A |
| Revenue Next Year | $51.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $2.54 |
| 52 Week High | $16.50 | $26.95 |
Technical Indicators
Market Signals| Indicator | PESI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 30.48 | 40.37 |
| Support Level | $10.04 | $6.65 |
| Resistance Level | $12.37 | $18.73 |
| Average True Range (ATR) | 0.81 | 0.95 |
| MACD | -0.20 | -0.21 |
| Stochastic Oscillator | 24.76 | 27.18 |
Price Performance
Historical ComparisonAbout PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).